Core Insights - Annovis Bio Inc. is advancing in late-stage clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD), showcasing the efficacy and safety of its drug [2][3] - The company will present data from its Phase 3 PD study and Phase 2/3 AD study at the AD/PD™ 2025 conference in Vienna [1][2] Company Overview - Annovis Bio is focused on developing transformative therapies for neurodegenerative diseases, particularly AD and PD, with a commitment to improving patient outcomes and quality of life [4] - The company is headquartered in Malvern, Pennsylvania, and actively engages with investors through updates and alerts [5][8] Conference Participation - Annovis will deliver two presentations: one on the cognitive and motor function improvements in early Parkinson's patients and another on the benefits of its drug for APOE4 carriers in Alzheimer's patients [3][7] - The company will also participate in a forum discussing novel approaches to accelerate the development of biomarkers and therapies related to PD and other neurological disorders [3]
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program